Who are Xanomeline Enteric Capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pilocarpine Ophthalmic Solution, Pilocarpine HCl, Low dose pilocarpine, Aceclidine ophthalmic solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xanomeline-enteric-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Xanomeline Enteric Capsule — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xanomeline Enteric Capsule (Xanomeline Enteric Capsule) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: muscarinic receptor agonist. Area: Neurology.

phase 3 muscarinic receptor agonist M1, M4 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Xanomeline Enteric Capsule (Xanomeline Enteric Capsule) — Bristol-Myers Squibb. Xanomeline is a muscarinic receptor agonist that targets the M1 and M4 subtypes.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Xanomeline Enteric Capsule TARGET	Xanomeline Enteric Capsule	Bristol-Myers Squibb	phase 3	muscarinic receptor agonist	M1, M4
Pilocarpine Ophthalmic Solution	Pilocarpine Ophthalmic Solution	Maastricht University Medical Center	marketed	Muscarinic receptor agonist	Muscarinic acetylcholine receptor (M3)
Pilocarpine HCl	Pilocarpine HCl	Allergan	phase 3	Muscarinic receptor agonist	Muscarinic M3 receptor
Low dose pilocarpine	Low dose pilocarpine	Ocuphire Pharma, Inc.	phase 3	Muscarinic receptor agonist	Muscarinic acetylcholine receptors (M3, M4)
Aceclidine ophthalmic solution	Aceclidine ophthalmic solution	LENZ Therapeutics, Inc	phase 3	Muscarinic receptor agonist	Muscarinic acetylcholine receptors (M1, M3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (muscarinic receptor agonist class)

Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xanomeline Enteric Capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/xanomeline-enteric-capsule. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing